Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Gains Access To Celera R&D For Infectious Disease Assays

This article was originally published in The Gray Sheet

Executive Summary

U.S. clinical lab evaluation of Celera Diagnostics' analyte-specific reagent hepatitis C test by year-end will be among the early milestones of the Applera unit's R&D and marketing agreement with Abbott

You may also be interested in...



AACC In Brief

Clinical lab test final rule: Software glitch delays implementation of Medicare final rule on clinical diagnostic laboratory tests from Nov. 25 to Jan. 1, 2003, American Society for Clinical Laboratory Science Executive VP Elissa Passiment tells participants at American Association for Clinical Chemistry annual meeting July 31 in Orlando. The delay will likely lead to discrepancies between Medicare national coverage decisions and local medical review policies, which may cause over-reimbursement in some instances, she claims. Surplus reimbursement of lab tests by local contractors during the period from Nov. 25 to Jan. 1 can be recouped, Passiment notes...

AACC In Brief

Clinical lab test final rule: Software glitch delays implementation of Medicare final rule on clinical diagnostic laboratory tests from Nov. 25 to Jan. 1, 2003, American Society for Clinical Laboratory Science Executive VP Elissa Passiment tells participants at American Association for Clinical Chemistry annual meeting July 31 in Orlando. The delay will likely lead to discrepancies between Medicare national coverage decisions and local medical review policies, which may cause over-reimbursement in some instances, she claims. Surplus reimbursement of lab tests by local contractors during the period from Nov. 25 to Jan. 1 can be recouped, Passiment notes...

Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%

Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months

Related Content

UsernamePublicRestriction

Register

MT016783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel